Advertisement

PentaVision

Ophthalmic Professional

Article

Update on the Glaucoma Drug Landscape

A look at the new pharmacologic options that are available or undergoing clinical trials.

Anthony P. Mai, MDTanner J. Ferguson, MD
Ophthalmic Professional January 1, 2025 Vol 14, Issue January 2025 Page(s): 11-12

Clinical Report: Update on the Glaucoma Drug Landscape

Overview

This report highlights recent advancements in glaucoma pharmacotherapy, including new drugs such as omidenepag isopropyl and sepetaprost, which offer novel mechanisms for lowering intraocular pressure (IOP). These developments are crucial as glaucoma remains the leading cause of irreversible blindness worldwide.

Background

Glaucoma is a significant public health concern, being the primary cause of irreversible blindness globally. The management of glaucoma primarily focuses on reducing IOP, the only modifiable risk factor for disease progression. Recent advancements in pharmacologic treatments and minimally invasive surgical options have expanded the therapeutic landscape, necessitating awareness among healthcare providers.

Data Highlights

{'table': {'columns': [{'name': 'Drug', 'type': 'string'}, {'name': 'IOP Reduction (mmHg)', 'type': 'string'}, {'name': 'Clinical Trial Phase', 'type': 'string'}], 'rows': [{'Drug': 'Omidenepag isopropyl', 'IOP Reduction (mmHg)': '4-6', 'Clinical Trial Phase': 'Phase 3'}, {'Drug': 'Sepetaprost', 'IOP Reduction (mmHg)': '6-7', 'Clinical Trial Phase': 'Phase 2'}, {'Drug': 'NCX 470', 'IOP Reduction (mmHg)': '~9', 'Clinical Trial Phase': 'Phase 2/3'}]}}

Key Findings

  • Omidenepag isopropyl lowers IOP by 4-6 mmHg and is noninferior to timolol.
  • Sepetaprost shows similar IOP reduction to latanoprost (6-7 mmHg) with fewer adverse events.
  • NCX 470 demonstrates superior IOP reduction compared to latanoprost and bimatoprost, with approximately 9 mmHg reduction.
  • QLS-101 is under investigation for its potential to lower episcleral venous pressure, which may benefit patients with normal tension glaucoma.
  • New therapies may improve patient adherence to treatment regimens.

Clinical Implications

Healthcare professionals should familiarize themselves with the latest glaucoma medications to better inform and support patients. Understanding the unique mechanisms and benefits of these new treatments can enhance patient compliance and management strategies.

Conclusion

The evolving landscape of glaucoma pharmacotherapy presents new opportunities for effective management, emphasizing the importance of ongoing education for healthcare providers.

References

  1. Glaucoma Physician, The Glaucoma Therapy Pipeline, 2020 -- Increasing expectations for glaucoma agents will be met.
  2. Glaucoma Physician, The Glaucoma Medication Pipeline, 2018 -- What new drugs will mean to glaucoma specialists and patients.
  3. Glaucoma Physician, New Developments in Medical Therapy, 2025 -- Sustained-release strategies and drugs that target episcleral venous pressure hold promise for the future of glaucoma management.
  4. Optometric Management, Acquire Medication Adherence Recommendations, 2022 -- Strategies to improve patient adherence to glaucoma medications.
  5. European Glaucoma Society -- Guidelines snapshot (2025–2026).
  6. European Glaucoma Society
  7. Frontiers | Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis
  8. iDose® TR (travoprost intracameral implant) – New drug approval